For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?
出版信息
Can J Hosp Pharm. 2020 Jan-Feb;73(1):58-61. Epub 2020 Feb 1.
Abstract
摘要
相似文献
1
For Primary Prevention, Should All Moderate- to High-Risk Patients Be Considered Candidates for Acetylsalicylic Acid?
Can J Hosp Pharm. 2020 Jan-Feb;73(1):58-61. Epub 2020 Feb 1.
2
[Acetylsalicylic acid for the primary prevention of cardiovascular disease in diabetic patients].
Ned Tijdschr Geneeskd. 2004 Jul 24;148(30):1481-5.
3
[Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
Ned Tijdschr Geneeskd. 2009;153:A109.
4
5
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Int J Stroke. 2015 Dec;10(8):1309-12. doi: 10.1111/ijs.12630. Epub 2015 Sep 30.
6
The Impact of Moderate-Dose Acetylsalicylic Acid in the Reduction of Inflammatory Cytokine and Prevention of Complication in Acute Phase of Kawasaki Disease: The Benefit of Moderate-Dose Acetylsalicylic Acid.
Children (Basel). 2020 Oct 16;7(10):185. doi: 10.3390/children7100185.
7
[Primary prevention of cardiovascular disease with acetylsalicylic acid: in high-risk patients].
Ned Tijdschr Geneeskd. 2005 Apr 16;149(16):853-4.
8
Personalized allocation of acetylsalicylic acid therapy for secondary prevention of coronary artery disease.
Front Cardiovasc Med. 2022 Sep 27;9:1004473. doi: 10.3389/fcvm.2022.1004473. eCollection 2022.
9
Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Adv Ther. 2020 Jul;37(7):3348-3369. doi: 10.1007/s12325-020-01398-8. Epub 2020 Jun 9.
10
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
BMC Neurol. 2015 Nov 2;15:225. doi: 10.1186/s12883-015-0480-4.
本文引用的文献
1
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.
2
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.
3
The rise and fall of aspirin in the primary prevention of cardiovascular disease.
Lancet. 2019 May 25;393(10186):2155-2167. doi: 10.1016/S0140-6736(19)30541-0.
4
Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
JAMA Cardiol. 2019 Aug 1;4(8):747-755. doi: 10.1001/jamacardio.2019.1880.
5
Aspirin for Primary Prevention of Cardiovascular Events.
J Am Coll Cardiol. 2019 Jun 18;73(23):2915-2929. doi: 10.1016/j.jacc.2019.03.501.
6
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2019 Sep 10;74(10):1376-1414. doi: 10.1016/j.jacc.2019.03.009. Epub 2019 Mar 17.
7
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.
8
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2019 Sep 10;140(11):e596-e646. doi: 10.1161/CIR.0000000000000678. Epub 2019 Mar 17.
9
Online decision aids for primary cardiovascular disease prevention: systematic search, evaluation of quality and suitability for low health literacy patients.
BMJ Open. 2019 Mar 13;9(3):e025173. doi: 10.1136/bmjopen-2018-025173.
10
Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
JAMA. 2019 Jan 22;321(3):277-287. doi: 10.1001/jama.2018.20578.
Zotero 插件